Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - Sanara MedTech Inc. | smti_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 25, 2021
SANARA MEDTECH INC.
|
(Exact
name of registrant as specified in its charter)
|
Texas
|
001-39678
|
59-2219994
|
(State
or other jurisdiction of
|
(Commission File
Number)
|
(IRS
Employer
|
incorporation)
|
|
Identification
No.)
|
|
|
|
1200 Summit Avenue, Suite 414
Fort Worth, Texas
|
|
76102
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (817) 529-2300
(Former
name or former address, if changed since last report)
Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common
Stock, $0.001 par value
|
|
SMTI
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition.
On
January 25, 2021, Sanara MedTech Inc. (the “Company”)
issued a press release announcing preliminary fourth quarter and
full year 2020 revenues and its preliminary year-end 2020 cash
balance. A copy of the Company’s press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
The
information in this Current Report on Form 8-K, including Exhibit
99.1 attached hereto, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth in such filing.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description
|
Press
Release issued January 25, 2021 (furnished pursuant to Item
2.02).
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
|
January 25, 2021
|
|
|
|
|
|
|
|
|
Sanara MedTech Inc.
|
|
|
|
|
|
|
|
By:
|
/s/
Michael D.
McNeil
|
|
|
|
Name:
Michael D. McNeil
|
|
|
|
Title:
Chief Financial Officer
|